Vaxart Inc
Suletud
0
Ülevaade
Aktsiahinna muutus
24h
Min
Max
Sissetulek | -50M 5.2M |
|---|---|
Müük | -65M 39M |
P/E Sektori keskmine | 3.938 49.701 |
Aktsiakasum | 0.02 |
Kasumimarginaal | 13.203 |
Töötajad | 65 |
EBITDA | -53M 5.2M |
Järgmine tulemuste avaldamine | 12. aug 2026 |
|---|
Turukapital | -31M 152M |
|---|---|
Eelmine avamishind | 0 |
Eelmine sulgemishind | 0 |
Tehniline skoor
By Trading Central
Kindlus
Bearish Evidence
Vaxart Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Vaxart Inc Prognoos
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
